Matthias Alder - Dec 7, 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role: Chief Executive Officer, Director
Signature: /s/ Jason Minio, Attorney-in-Fact
Stock symbol: GANX
Transactions as of: Dec 7, 2023
Transactions value $: -$4,550
Form type: 4
Date filed: 12/14/2023, 04:01 PM
Previous filing: Oct 3, 2023
Next filing: Dec 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GANX	Common Stock	Sale	-$4.55K	-1.82K	-27.27%	$2.50	4.86K	Dec 7, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects shares sold to cover withholding taxes incurred upon the vesting and settlement of restricted stock units in a trade that was initiated by the Issuer on the Reporting Person's behalf.
F2	The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.48 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range specified in this footnote.

Content

Reflects shares sold to cover withholding taxes incurred upon the vesting and settlement of restricted stock units in a trade that was initiated by the Issuer on the Reporting Person's behalf.

The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.48 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range specified in this footnote.